Security key
M53071201
IceCure Medical Ltd. - Ordinary Shares, no par value (ICCM)
CUSIP: M53071201
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / Ordinary Shares, no par value
- Total 13F shares
- 20,680
- Total 13F value
- $4,132
- Share change
- +229
- SEC-reported price per share
- $0.88
- Number of holders
- 2
- Value change
- +$370
- Number of buys
- 1
- Shares outstanding
- 3,006,326
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
2
Top holders
2
ICCM full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q2 2026
IceCure Medical Ltd. SEC filings
IceCure Medical Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M53071201
Recent filing periods:
Ownership snapshot
Top reported holders of ICCM - IceCure Medical Ltd. - Ordinary Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Haixiang Li
Disclosed value leader
Haixiang Li
Comparable rows
2/15
Latest evidence
14 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 46%
13 rows are not safely comparable across share classes.
13D/G row: Haixiang Li
Showing 1-6 of 15 holder rows.
Quick read
Haixiang Li leads the comparable SEC ownership view at 46%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Haixiang Li's linked filing trail.
Comparable ownership
Top 2
Haixiang Li
46%
ARMISTICE CAPITAL, LLC
10%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Haixiang Li |
13D/G
Mr. Li Haixiang
|
46%
Reported 13D/G
· 17 Mar 2026
|
$20,791,026
35,846,597 shares
|
+$5,800,000 | 17 Mar 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
10%
Reported 13D/G
· 30 Jun 2026
|
$1,063,175
300,332 shares
|
$0 | 30 Jun 2026 |
| Meir Peleg |
3/4/5
Chief Financial Officer
|
—
denominator unverified
|
$946,825
194,816 shares
|
— | 14 Aug 2026 |
| Shay Levav |
3/4/5
Chief Operating Officer
|
—
denominator unverified
|
$711,047
146,303 shares
|
— | 14 Aug 2026 |
| Shad Good |
3/4/5
VP, Sales for North America
|
—
denominator unverified
|
$664,365
136,698 shares
|
— | 14 Aug 2026 |
| Tlalit Bussi Tel-Tzure |
3/4/5
VP, BD & Global Marketing
|
—
denominator unverified
|
$517,688
106,518 shares
|
— | 14 Aug 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
20,680
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
10
Q3 2026 holders
2
Holder diff
-8
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend